PTC THERAPEUTICS, INC. Quarterly Income Tax Expense (Benefit) in USD from Q2 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Ptc Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2015 to Q2 2024.
  • Ptc Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $13.4M.
  • Ptc Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was -$14.6M, a 79.6% increase year-over-year.
  • Ptc Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was -$69.5M, a 144% decline from 2022.
  • Ptc Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was -$28.5M, a 612% decline from 2021.
  • Ptc Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was $5.56M, a 84.2% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$14.6M $13.4M +$52M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$66.6M $6.88M +$2.91M +73.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-04-25
Q4 2023 -$69.5M -$1.26M +$17.5M +93.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 -$87.1M -$33.6M -$15.7M -87.9% Jul 1, 2023 Sep 30, 2023 10-Q 2023-10-26
Q2 2023 -$71.3M -$38.6M -$42M -1238% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$29.3M $3.97M -$866K -17.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-04-25
Q4 2022 -$28.5M -$18.8M -$23.5M -504% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 -$5.01M -$17.9M -$17.9M -49603% Jul 1, 2022 Sep 30, 2022 10-Q 2023-10-26
Q2 2022 $12.8M $3.39M +$2.9M +595% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $9.95M $4.84M +$4.38M +972% Jan 1, 2022 Mar 31, 2022 10-Q 2023-04-27
Q4 2021 $5.56M $4.66M -$7.98M -63.1% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 $13.5M -$36K -$22.3M -100% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-27
Q2 2021 $35.9M $488K +$404K +481% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $35.5M $451K +$229K +103% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q4 2020 $35.2M $12.6M +$1.99M +18.7% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-21
Q3 2020 $33.2M $22.3M +$22.6M Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-28
Q2 2020 $10.6M $84K -$690K -89.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 $11.3M $222K -$354K -61.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $11.7M $10.6M +$11.6M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-22
Q3 2019 $12K -$344K -$699K -197% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-29
Q2 2019 $711K $774K +$385K +99% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $326K $576K +$355K +161% Jan 1, 2019 Mar 31, 2019 10-Q 2020-04-30
Q4 2018 -$29K -$994K -$1.82M -220% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 $1.79M $355K +$164K +85.9% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-30
Q2 2018 $1.63M $389K +$239K +159% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $1.39M $221K +$56K +33.9% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 $1.34M $829K +$465K +128% Oct 1, 2017 Dec 31, 2017 10-K 2020-03-02
Q3 2017 $870K $191K +$7K +3.8% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-05
Q2 2017 $863K $150K +$243K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $620K $165K +$51K +44.7% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $569K $364K Oct 1, 2016 Dec 31, 2016 10-K 2019-03-01
Q3 2016 $184K +$96K +109% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-02
Q2 2016 -$93K -$238K -164% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $114K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-08
Q3 2015 $88K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-03
Q2 2015 $145K Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.